The company's FDA-approved drug Sofdra is the first for the common and embarrassing condition of excessive sweating.

This development is part of Botanix’s strategy to expand payer coverage, now reaching over 110 million commercial lives, for its novel treatment targeting primary axillary hyperhidrosis, a condition ...

Botox is one of the significant advances in dealing with hyperhidrosis: a practical, noninvasive, and long-term solution to a situation that, properly allowed to develop, can adversely affect ...

The main indication for these products is as a first-line treatment for mild axillary hyperhidrosis. Oral anticholinergic agents such as glycopyrrolate or amitriptyline represent the main systemic ...

Botanix Pharmaceuticals Limited (AU:BOT) has released an update. Botanix Pharmaceuticals Limited is set to make waves in the dermatology market ...